Hyrimoz Injection, Solution
Product Images NDC 61314-454

Product Visual Gallery

This gallery contains 72 technical images submitted to the FDA as part of the official labeling for Hyrimoz (NDC 61314-454). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sandoz Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig 1 (Gp2017 Fig1)

A line graph comparing the percentage of ACR20 responders over time (in weeks) between a group receiving 40 mg of medication every other week and a placebo group. The y-axis shows percent ACR20 responders, and the x-axis shows time in weeks up to 48.*

FDA Label Image

Fig 2 (Gp2017 Fig2)

A line graph comparing the percentage of ASAS 20 Response over 26 weeks between Placebo (N=107) and Adalimumab (N=208). The Adalimumab group shows a higher and sustained response compared to the Placebo group throughout the time period.*

FDA Label Image

Fig-3a (Image 45)

A line graph showing treatment failure rate over time (months) comparing placebo and adalimumab groups. The x-axis represents the time in months, while the y-axis shows the treatment failure rate percentage. The graph includes numerical data on the number of patients at risk for each treatment over time.*

FDA Label Image

Fig-3b (Image 46)

A line graph comparing treatment failure rates over a 20-month period for three groups: placebo, Adalimumab, and P80/111. The vertical axis represents treatment failure rate percentage from 0 to 100, and the horizontal axis shows time in months from 0 to 20. The graph indicates lower treatment failure rates for Adalimumab and higher rates for placebo over time, with P80/111 showing intermediate results.*

FDA Label Image

Figure-4 (Image 48)

A Kaplan-Meier survival curve chart showing the probability of failing treatment over time in weeks. Two lines compare treatment groups: adalimumab with a solid line and placebo with a dashed line. The chart includes numbers of patients at risk at various time points for both groups, illustrating lower failure rates over time with adalimumab compared to placebo.*

FDA Label Image

Figa (Image 04)

An instructional diagram of an injection syringe illustrating its parts including the needle cap, needle guard, viewing window with label and expiration date, finger flange, needle guard wings, plunger, and plunger head.*

FDA Label Image

Figb (Gp2017 Figc)

An instructional illustration showing four items in sequence: a wipe packet labeled 'WIPE,' a rounded cotton ball or pad, a container labeled 'SHARPS' for disposing needles, and an adhesive bandage strip. This likely depicts steps for preparing and cleaning an injection site and properly disposing of the needle and covering the site afterward.*

FDA Label Image

Figc (Image 05)

An illustration of a prefilled syringe device used for subcutaneous injection. The syringe includes a barrel with measurement markings, a plunger, and a protective needle guard. This device is consistent with those used for administering HYRIMOZ (adalimumab-adaz) injection solution.*

FDA Label Image

Figd (Image 06)

Illustration showing a safety mechanism of a prefilled syringe used for subcutaneous injection. The diagram depicts the syringe barrel with a needle shield and a plunger, highlighting the needle retraction or safety feature typically found on HYRIMOZ (adalimumab-adaz) injection devices.*

FDA Label Image

Fige (Image 01)

An illustration showing recommended subcutaneous injection sites on the human body. Dark shaded areas indicate the lower abdomen and the front thighs as preferred injection locations.*

FDA Label Image

Figf (Image 02)

An instructional illustration showing a hand performing a circular rubbing motion on the skin, likely demonstrating a technique for administering a subcutaneous injection, as relevant for HYRIMOZ (adalimumab-adaz) injection solution.*

FDA Label Image

Figg (Image 07)

An instructional diagram showing a hand removing the protective cap from a syringe needle by pulling it straight off. The syringe is held in the other hand, indicating preparation for subcutaneous injection.*

FDA Label Image

Figh (Image 08)

An instructional illustration showing a person administering an injection into the finger using a prefilled syringe or injection device. The diagram depicts one hand holding the injection device and the other hand stabilizing the finger for subcutaneous injection.*

FDA Label Image

Figi (Image 09)

An instructional diagram showing a close-up of a person administering a subcutaneous injection using a syringe or injector pen. The illustration highlights the needle being positioned against the skin with a detailed zoom-in on the injector mechanism, emphasizing proper finger placement and injection technique.*

FDA Label Image

Figj (Image 10)

An instructional illustration showing a hand holding a prefilled injection device intended for subcutaneous administration. The image depicts pressing the plunger at the top of the device with a thumb while the needle is directed downwards, illustrating the injection process.*

FDA Label Image

Figk (Image 11)

An instructional illustration showing a hand holding a prefilled syringe, with the thumb pushing the plunger upward, indicating the action of administering a subcutaneous injection using the syringe.*

FDA Label Image

Figl (Image 03)

An instructional illustration showing a hand disposing of a used syringe into a labeled sharps container. The image demonstrates proper disposal of injection equipment to ensure safety and hygiene.*

FDA Label Image

Figa (Figa)

An instructional diagram of the HYRIMOZ prefilled syringe showing labeled parts including needle cap, needle guard, viewing window with label and expiration date, finger flange, needle guard wings, plunger, and plunger head. The syringe is designed for subcutaneous injection of adalimumab-adaz solution.*

FDA Label Image

Figb (Image 34)

An instructional illustration showing a sequence of items: a wipe packet labeled 'WIPE,' a cotton ball or pad, a sharps disposal container labeled 'SHARPS,' and a bandage strip. The items are arranged with plus signs between them, suggesting steps or components related to injection site preparation and post-injection care.*

FDA Label Image

Figc (Image 35)

Illustration of a syringe device containing a solution for injection. The syringe has a plunger and a needle covered by a protective cap, consistent with a subcutaneous injection dosage form.*

FDA Label Image

Figd (Image 36)

An instructional diagram showing a subcutaneous injection device with a needle covered by a protective shield and a plunger mechanism, likely representing how to use the HYRIMOZ (adalimumab-adaz) prefilled syringe for injection.*

FDA Label Image

Fige (Image 37)

An instructional diagram showing appropriate subcutaneous injection sites on a human body. The highlighted areas include the abdomen around the navel and the front thighs, indicating where HYRIMOZ (adalimumab-adaz) injection solution can be administered.*

FDA Label Image

Figf (Image 38)

An instructional illustration showing a hand rubbing or massaging the skin on a thigh, likely demonstrating preparation or injection technique for a subcutaneous injection.*

FDA Label Image

Figg (Image 39)

An instructional illustration showing a hand removing the needle cap from a syringe. The syringe is held ready for subcutaneous injection, demonstrating proper needle preparation technique.*

FDA Label Image

Figh (Image 40)

An instructional line drawing showing one hand holding a syringe to administer a subcutaneous injection into the skin of the other hand's finger area. The syringe is partially inserted, demonstrating injection technique.*

FDA Label Image

Figi (Image 41)

An instructional diagram illustrating the handling of a subcutaneous injection device, possibly a prefilled syringe. It shows a close-up of the fingers gripping the device and a detailed inset focusing on the needle cover area, highlighting the step of removing or preparing the needle for injection.*

FDA Label Image

Figj (Image 42)

Illustration showing a hand holding a prefilled syringe injection device, with arrows indicating pressing the thumb on the plunger to administer the subcutaneous injection. The image demonstrates proper technique for using an injection device, relevant for HYRIMOZ (adalimumab-adaz) subcutaneous injection.*

FDA Label Image

Figk (Image 43)

An instructional illustration showing a hand holding a prefilled syringe used for subcutaneous injection. The illustration depicts the thumb removing the cap from the syringe by pulling it upward, preparing the injection device for use.*

FDA Label Image

Figl (Image 44)

An instructional illustration showing a hand holding a used syringe above a sharps disposal container labeled "SHARPS," depicting proper disposal technique for injection needles or syringes, likely related to the subcutaneous administration of HYRIMOZ (adalimumab-adaz) injection.*

FDA Label Image

Figaa (Image 13)

An instructional diagram of a prefilled injection pen showing and labeling parts including the needle, needle guard, cap, internal needle cover, and viewing window. The diagram visually explains the components of the injection device for subcutaneous administration.*

FDA Label Image

Figbb (Image 14)

An instructional illustration showing four items in sequence for injection preparation or aftercare: a wipe, a cotton ball or gauze pad, a container labeled 'SHARPS' for disposing used needles, and a bandage strip for covering the injection site.*

FDA Label Image

Figcc (Image 15)

An illustration of a HYRIMOZ injection pen showing the viewing window and expiration date area. The pen is depicted with a cap on one end and an arrow indicating removal or direction.*

FDA Label Image

Fig E (Gp2017 Fige)

An anatomical illustration showing recommended subcutaneous injection sites for HYRIMOZ (adalimumab-adaz). Shaded areas indicate injection zones on the lower abdomen and the front thighs of a standing human figure.*

FDA Label Image

Figee (Gp2017 Figf)

An instructional illustration showing a hand pinching the skin of a thigh with arrows indicating the motion, likely demonstrating how to prepare the injection site for a subcutaneous injection. The surrounding context suggests proper technique for administering an injection with the product HYRIMOZ (adalimumab-adaz).*

FDA Label Image

Figff (Gp2017 Figg)

Illustration showing hands preparing a HYRIMOZ prefilled syringe by removing the cap from the needle end in preparation for subcutaneous injection. The image demonstrates the correct method to detach the cap before administration.*

FDA Label Image

Figgg (Gp2017 Figh1)

An instructional illustration showing the correct and incorrect ways to hold an injectable pen device. The correct method is depicted upright with a green checkmark and the word 'Correct.' The incorrect method is shown angled with a black X and the word 'Incorrect.' This image helps guide proper handling for injection.*

FDA Label Image

Figgg1 (Gp2017 Figh)

An instructional illustration shows a hand holding a prefilled syringe in a vertical position above a surface, likely demonstrating how to prepare the syringe for subcutaneous injection of HYRIMOZ (adalimumab-adaz) injection solution.*

FDA Label Image

Fighh (Gp2017 Figi)

An instructional illustration showing a hand holding a syringe for subcutaneous injection. A downward arrow indicates pressing the syringe plunger to administer the injection, typically into the skin surface.*

FDA Label Image

Figii (Gp2017 Figj)

An instructional illustration showing a hand holding and pressing down a pre-filled syringe for injection, with the needle tip positioned against a surface. A green dashed circle highlights the syringe plunger area, emphasizing the act of administering the injection.*

FDA Label Image

Figjj (Gp2017 Figk)

An instructional illustration depicting a hand holding a prefilled syringe, demonstrating the proper grip for administering a subcutaneous injection with the HYRIMOZ (adalimumab-adaz) injection, solution.*

FDA Label Image

Figkk (Gp2017 Figl)

An instructional diagram showing a needle positioned above a container labeled 'SHARPS,' with a downward arrow indicating disposal of the needle into the sharps container. The image likely relates to proper disposal of injection needles or syringes.*

FDA Label Image

Figaa (Figaa)

An instructional diagram illustrating the parts of a prefilled syringe or pen injection device, including the needle, needle guard, cap, internal needle cover, and viewing window. The image displays the syringe separated from the cap to show these components clearly.*

FDA Label Image

Figbb (Image 12)

An instructional illustration showing four items in sequence: a wipe, a cotton ball or pad, a sharps disposal container, and an adhesive bandage. The image likely represents steps or materials used for safe subcutaneous injection procedures or post-injection care.*

FDA Label Image

Figcc (Image 16)

An illustration of a HYRIMOZ prefilled syringe showing the viewing window near the middle of the syringe barrel and an expiration date (EXP) printed on the syringe. The syringe is designed for subcutaneous injection of adalimumab-adaz solution.*

FDA Label Image

Fig E (Image 17)

An anatomical illustration showing a front view of a human torso and upper legs. Dark shaded areas highlight recommended subcutaneous injection sites on the abdomen below the navel and on the front thighs.*

FDA Label Image

Figee (Image 18)

An instructional illustration showing a hand pinching skin on a thigh, with arrows indicating a side-to-side motion. This diagram appears to demonstrate how to properly prepare or administer a subcutaneous injection.*

FDA Label Image

Figff (Image 19)

An instructional line drawing showing two hands preparing a prefilled pen injection device. One hand holds the pen, while the other removes the cap by pulling it away with an arrow indicating the direction to take off the cap. This likely depicts the first step in using the HYRIMOZ adalimumab-adaz subcutaneous injection.*

FDA Label Image

Figgg (Image 20)

An instructional illustration showing the correct and incorrect positioning of a syringe or injection pen vertically upright. The left image with a green check mark indicates the correct upright position, while the right image with a black X shows an incorrect tilted angle.*

FDA Label Image

Figgg1 (Image 21)

An instructional illustration showing a hand holding a prefilled syringe vertically, preparing for a subcutaneous injection. The syringe appears to be filled with medication and is oriented with the needle end pointing downward toward the injection site.*

FDA Label Image

Fighh (Image 22)

An instructional illustration showing a hand holding a prefilled syringe, positioned for subcutaneous injection with a downward arrow indicating the direction of injection. The image represents the use of HYRIMOZ (adalimumab-adaz) injection, solution for subcutaneous administration.*

FDA Label Image

Figii (Image 23)

An instructional illustration showing a hand holding a syringe with the thumb pressing down on the plunger, demonstrating injection technique. A green dotted circle highlights the plunger area, indicating proper use for subcutaneous administration.*

FDA Label Image

Figjj (Image 24)

An instructional illustration showing a hand holding a prefilled syringe with a green plunger, demonstrating the proper grip for administering a subcutaneous injection.*

FDA Label Image

Figkk (Image 25)

An instructional illustration showing proper disposal of a used syringe by inserting it downward into a labeled container marked "SHARPS." This image guides safe handling of injection waste, relevant to subcutaneous injection products like HYRIMOZ (adalimumab-adaz).*

FDA Label Image

Figure 10a (Image 27)

Illustration of a Hyrimoz adalimumab-adaz injection device showing labeled parts: plunger rod, finger grip, and needle cap. The image highlights the components of the subcutaneous injection pen.*

FDA Label Image

Figure 10b (Figure 10b)

An instructional illustration showing four items in sequence used for injection site care: an antiseptic wipe labeled "WIPE," a circular cotton ball or pad, a container labeled "SHARPS" for disposing needles, and an adhesive bandage.*

FDA Label Image

Figure 10c (Image 28)

An anatomical illustration showing preferred subcutaneous injection sites for HYRIMOZ (adalimumab-adaz) on a simplified human torso and legs. Shaded areas indicate the abdomen around the navel and the front of both thighs as recommended injection locations.*

FDA Label Image

Figure 10d (Image 29)

An instructional illustration showing a hand cleaning a thigh area with a wipe using circular motions, likely preparing the site for a subcutaneous injection.*

FDA Label Image

Figure 10e (Image 30)

An instructional illustration showing a person's hand removing a needle cap from a syringe containing a solution for injection. The syringe appears to be prepared for a subcutaneous injection, consistent with the use of HYRIMOZ (adalimumab-adaz) injection solution.*

FDA Label Image

Figure 10f (Image 31)

An instructional diagram showing a hand holding a syringe at a 45-degree angle to the skin surface for subcutaneous injection. The illustration demonstrates the proper angle to insert the needle for an injection, consistent with subcutaneous administration technique.*

FDA Label Image

Figure 10g (Image 32)

An instructional diagram showing a person preparing a subcutaneous injection using a syringe. The image highlights the proper grip and positioning of the syringe for administering an injection, including a zoomed-in view of the syringe's plunger and finger placement.*

FDA Label Image

Figure 10h (Image 33)

An instructional illustration showing a hand dropping a used syringe with needle into a labeled sharps disposal container marked 'SHARPS.' This diagram emphasizes safe disposal of injection equipment.*

FDA Label Image

40-08-pfs-label (Gp2017 Syringe)

HYRIMOZ 40 mg/0.8 mL injection label showing dosage form as subcutaneous injection in prefilled syringe. The label includes the active ingredient adalimumab-adaz and is manufactured by Sandoz Inc. The label contains directions for use, medication guide notes, and cautions for proper administration.*

FDA Label Image

40-08-pen-label (Gp2017 Pen)

HYRIMOZ 40 mg/0.8 mL injection label for subcutaneous use, containing adalimumab-adaz. The label indicates two single-dose prefilled Sensoready pens per carton with needle cover, no preservatives, and includes patient medication guides. Labeler is Sandoz Inc, a Novartis Division.*

FDA Label Image

10-01-pfs-label (10 01 Image.jpb)

HYRIMOZ 10 mg/0.1 mL injection prefilled syringes label for adalimumab-adaz by Sandoz. The label states it is for subcutaneous use only and includes 2 single-dose prefilled syringes per carton. It notes the syringes contain no preservatives and are not made with natural rubber latex. The label also shows the NDC 61314-509-64 and a syringe illustration.*

FDA Label Image

20-02-pfs-label (20 02 Pfs Image)

HYRIMOZ 20 mg/0.2 mL injection, solution for subcutaneous use in single-dose prefilled syringes. The sterile solution contains adalimumab-adaz with no preservatives and is a clear, colorless to pale yellow solution. The package includes two prefilled syringes and the labeler is Sandoz Inc. The label instructs dispensing the enclosed Medication Guide to each patient.*

FDA Label Image

20-04-pfs-label (20 04 Pfs Image)

The HYRIMOZ 20 mg/0.4 mL injection packaging label features brand and generic names (adalimumab-adaz) with a green highlight on the strength. It is labeled for subcutaneous use only, supplied with a 2 mL glass prefilled injectable syringe. The label includes usage and safety instructions, with the manufacturer Sandoz Inc. logo visible on the side.*

FDA Label Image

40-04-pen-label (40 04 Pen Image)

HYRIMOZ 40 mg/0.4 mL injection label showing the product as an adalimumab-adaz subcutaneous injection in a single-dose prefilled syringe with 29 gauge needle. The label highlights it is a Sandoz Inc product and includes patient education instructions, emphasizing the enclosed Medication Guide for each patient.*

FDA Label Image

40-04-pen-sample-label (Image 47)

HYRIMOZ 40 mg/0.4 mL injection, a subcutaneous solution of adalimumab-adaz, is presented in a carton containing 2 single-dose prefilled Sensoready pens. The label notes it is a sterile solution without preservatives, not made with natural rubber latex, and is for prescription use only. Manufacturer is Sandoz Inc.*

FDA Label Image

80-08-pen-label (80 08 Pen Image)

Hyrimoz (adalimumab-adaz) Injection 80 mg/0.8 mL subcutaneous injection starter pack by Sandoz Inc. The carton includes 3 single-dose prefilled Sensoready pens. The label notes it is for Crohn's Disease and Ulcerative Colitis, for subcutaneous use only, and contains instructions and components inside the starter package.*

FDA Label Image

80-40-3pen-fb (80 40 Pen Image)

HYRIMOZ (adalimumab-adaz) Injection plaque psoriasis starter pack label for subcutaneous use. The pack contains three single-dose prefilled Sensoready pens with two dosages: 80 mg/0.8 mL and 40 mg/0.4 mL. Label includes instructions on use, medication guide, prescribing information, and quick reference guide. Manufactured by Sandoz Inc.*

FDA Label Image

80-08-pfs-label (80 08 Pfs Image)

Packaging label of Hyrimoz (adalimumab-adaz) injection, solution for subcutaneous use, pediatric Crohn's disease starter pack for patients weighing 40 kg or more. The pack includes three single-dose prefilled syringes, each containing 80 mg/0.8 mL. Labeler is Sandoz Inc. The label highlights medication guide inclusion and syringe needle guard features.*

FDA Label Image

80-40-2pfs-label (80 40 Pfs Image)

HYRIMOZ injection for subcutaneous use, pediatric Crohn's disease starter pack by Sandoz Inc. The label highlights adalimumab-adaz with prefilled syringes in 80 mg/0.8 mL and 40 mg/0.4 mL strengths. Designed for pediatric patients under 40 kg, it includes syringes with needle guards and instructions for use.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.